Drug Search Results
More Filters [+]


Alternative Names: auranofin, ridaura
Latest Update: 2024-03-18
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TR Inhibitor,NF-KB Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Canada | Colombia | Germany | India | Ireland | Italy | New Zealand | Norway | Pakistan | Peru | Portugal | Slovenia | South Africa | Sweden | Taiwan | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Auranofin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events